Expert United Kingdom consensus on the preservation of joint health in people with moderate and severe haemophilia A: A modified Delphi panel.
Delphi method
United Kingdom
haemophilia A
joint pain
joints
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
19 Jan 2024
19 Jan 2024
Historique:
revised:
20
12
2023
received:
07
11
2023
accepted:
30
12
2023
medline:
19
1
2024
pubmed:
19
1
2024
entrez:
19
1
2024
Statut:
aheadofprint
Résumé
For people with haemophilia A (PwHA), bleeding in the joints leads to joint damage and haemophilia-related arthropathy, impacting range of motion and life expectancy. Existing guidelines for managing haemophilia A support healthcare professionals (HCPs) and PwHA in their efforts to preserve joint health. However, such guidance should be reviewed, considering emerging evidence and consensus as presented in this manuscript. Fifteen HCPs experienced in the management of PwHA in the UK participated in a three-round Delphi panel. Consensus was defined at ≥70% of panellists agreeing or disagreeing for Likert-scale questions, and ≥70% selecting the same option for multiple- or single-choice questions. Questions not reaching consensus were revised for the next round. 26.8% (11/41), 44.8% (13/29) and 93.3% (14/15) of statements reached consensus in Rounds 1, 2 and 3, respectively. HCPs agreed that prophylaxis should be offered to patients with a baseline factor VIII (FVIII) level of ≤5 IU/dL and that, where there is no treatment burden, the aim of prophylaxis should be to achieve a trough FVIII level ≥15 IU/dL and maintain a longer period with FVIII levels of ≥20-30 IU/dL to provide better bleed protection. The aspirational goal for PwHA is to prevent all joint bleeds, which may be achieved by maintaining normalised (50-150 IU/dL) FVIII levels. The panel of experts were largely aligned on approaches to preserving joint health in PwHA, and this consensus may help guide HCPs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Sobi Ltd
Informations de copyright
© 2024 The Authors. Haemophilia published by John Wiley & Sons Ltd.
Références
Benson G, Auerswald G, Dolan G, et al. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus. 2018;16(6):535-544.
Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26:1-158.
Simpson ML, Valentino LA. Management of joint bleeding in hemophilia. Expert Rev Hematol. 2012;5(4):459-468.
World Federation of Hemophilia. Chronic hemophilic synovitis: the role of radiosynovectomy 2004. https://www1.wfh.org/publication/files/pdf-1176.pdf
Mancuso ME, Holstein K, O‘Donnell JS, et al. Synovitis and joint health in patients with haemophilia: statements from a European e-Delphi consensus study. Haemophilia. 2023;29(2):619-628.
Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorb. 2011;1(1):51-59.
McLaughlin P, Hurley M, Chowdary P, Stephensen D, Khair K. How does a lifetime of painful experiences influence sensations and beliefs about pain in adults with severe haemophilia? A qualitative study. Disabil Rehabil. 2022;44(26):8412-8419.
Skinner MW, Nugent D, Wilton P, et al. Achieving the unimaginable: health equity in haemophilia. Haemophilia. 2020;26(1):17-24.
Gooding R, Thachil J, Alamelu J, Motwani J, Chowdary P. Asymptomatic joint bleeding and joint health in hemophilia: a review of variables, methods, and biomarkers. J Blood Med. 2021;12:209-220.
Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
Scott MJ, Xiang H, Hart DP, et al. Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: the THUNDER study. Haemophilia. 2019;25(2):205-212.
Collins PW, Obaji SG, Roberts H, Gorsani D, Rayment R. Clinical phenotype of severe and moderate haemophilia: who should receive prophylaxis and what is the target trough level? Haemophilia. 2021;27(2):192-198.
Rayment R, Chalmers E, Forsyth K, et al. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol. 2020;190(5):684-695.
Tagliaferri A, Feola G, Molinari AC, et al. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thromb Haemost. 2015;114(07):35-45.
Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125(13):2038-2044.
Hsu C-C, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12(1):1-8.
Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliative Med. 2017;31(8):684-706.
Den Uijl I, Mauser Bunschoten E, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia. 2011;17(6):849-853.
Klamroth R, Windyga J, Radulescu V, et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood. 2021;137(13):1818-1827.
Valentino LA, Pipe SW, Collins PW, et al. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia. 2016;22(4):514-520.
McLaughlin P, Hermans C, Asghar S, et al. Problem joints and their clinical and humanistic burden in children and adults with moderate and severe hemophilia A: cHESS paediatrics and CHESS II. Blood. 2020;136:33-34.
Konkle BA, Skinner M, Iorio A. Hemophilia trials in the twenty-first century: defining patient important outcomes. Res Pract Thromb Haemost. 2019;3(2):e12195.
Valentino L. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia. 2004;10(2):147-157.
United Kingdom Haemophilia Centre Doctors' Organisation. UKHCDO Annual Report 2022. http://www.ukhcdo.org/wp-content/uploads/2022/12/UKHCDO-Annual-Report-2022-2021-22-Data.pdf